Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Wang, Peili  [Clear All Filters]
Journal Article
Wang Y, Zhou W, Chen J, Chen J, Deng P, Chen H, Sun Y, Yu Z, Pang D, Liu L, et al. Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma. MedComm (2020). 2023;4(4):e284.
Yu Z, Deng P, Chen Y, Lin D, Liu S, Hong J, Guan P, Chen J, Zhong M-E, Chen J, et al. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer. Proc Natl Acad Sci U S A. 2024;121(6):e2304619121.
Hong JHan, Yong CHan, Heng HLee, Chan JYongsheng, Lau MChan, Chen J, Lee JYi, Lim AHerbert, Li Z, Guan P, et al. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies. Gut. 2023.
Xiao G, Lu W, Yuan J, Liu Z, Wang P, Fan H. Fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/β-catenin pathway inhibition. J Transl Med. 2024;22(1):99.
Chen J, Hong JHan, Huang Y, Liu S, Yin J, Deng P, Sun Y, Yu Z, Zeng X, Xiao R, et al. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023;22(1):85.
Song Y, Cheng X, Yang X, Zhao R, Wang P, Han Y, Luo Z, Cao Y, Zhu C, Xiong Y, et al. Early growth response-1 facilitates enterovirus 71 replication by direct binding to the viral genome RNA. Int J Biochem Cell Biol. 2015.